Advertisement

Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure

  • Elizabeth Smyth
  • Siobhan Glavey
  • Dario Melotti
  • Patrick Thornton
  • Jeremy Sargent
  • Peter Conlon
  • Philip Murphy
  • John QuinnEmail author
Letter to the Editor
  • 65 Downloads

Keywords

Daratumumab Dialysis-dependant renal failure Dialysis independence Multiple myeloma 

Notes

Compliance with ethical standards

Informed consent

The patient gave informed consent for this letter to be written.

References

  1. 1.
    Evison F, Sangha J, Yadav P, Aung YS, Sharif A, Pinney JA, Drayson MT, Cook M, Cockwell P (2018) A population-based study of the impact of dialysis on mortality in multiple myeloma. Br J Haematol 180(4):588–591 https://www.ncbi.nlm.nih.gov/pubmed/27766629 CrossRefGoogle Scholar
  2. 2.
    Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG (2010) Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 25(2):419–426 https://www.ncbi.nlm.nih.gov/pubmed/19767634 CrossRefGoogle Scholar
  3. 3.
    Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N (2011) Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 22(6):1129–1136 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103732/ CrossRefGoogle Scholar
  4. 4.
    Yadav P, Hutchison CA, Basnayake K et al (2016) Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury. Eur J Haematol 96(6):610–617 https://www.ncbi.nlm.nih.gov/pubmed/26248588 CrossRefGoogle Scholar
  5. 5.
    Lokhorst HM, Plesner T, Laubach JP et al (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207–1219 https://www.ncbi.nlm.nih.gov/pubmed/26308596 CrossRefGoogle Scholar
  6. 6.
    Rocchi S, Tacchetti P, Pantani L, Mancuso K, Zannetti B, Cavo M, Zamagni E (2018) Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica 103(6):e277–e278 https://www.ncbi.nlm.nih.gov/pubmed/29622654 CrossRefGoogle Scholar
  7. 7.
    Dimopoulos MA, Roussou M, Gavriatopoulou M et al (2017) Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J 16(7):6 https://www.ncbi.nlm.nih.gov/pubmed/28622304 Google Scholar
  8. 8.
    Dimopoulos M, Weisel K, van de Donck NWJC et al (2018) Pomalidomide plus low-dose dexamethasone in patients with Relapsed/refractory multiple myeloma and renal impairment: results from a phase II trial. J Clin Oncol 36(20):2035–2043 https://www.ncbi.nlm.nih.gov/pubmed/29394124 CrossRefGoogle Scholar
  9. 9.
    Chanan-Khan AA, Kaufman JL, Mehta J et al (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109(6):2604–2606 https://www.ncbi.nlm.nih.gov/pubmed/17138816 CrossRefGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2018

Authors and Affiliations

  • Elizabeth Smyth
    • 1
  • Siobhan Glavey
    • 1
  • Dario Melotti
    • 1
  • Patrick Thornton
    • 1
  • Jeremy Sargent
    • 1
  • Peter Conlon
    • 2
  • Philip Murphy
    • 1
  • John Quinn
    • 1
    Email author
  1. 1.Department of HaematologyBeaumont HospitalBeaumontIreland
  2. 2.Department of NephrologyBeaumont HospitalBeaumontIreland

Personalised recommendations